Oppenheimer raised the firm’s price target on Crinetics (CRNX) to $87 from $73 and keeps an Outperform rating on the shares. The firm has made revisions to its Crinetics model following Palsonify’s FDA approval for acromegaly. Oppenheimer now projects 2026-2028 global Palsonify sales of $60M, 214M, and 419M vs. Visible Alpha consensus of $54M, 166M, and 300M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Crinetics price target raised to $75 from $58 at Stifel
- Crinetics price target raised to $77 from $65 at Morgan Stanley
- Trump threatens new tariffs on drugs, kitchen cabinets, trucks: Morning Buzz
- Crinetics rises 25.7%
- Crinetics rises 21.9%